Description
Citrullinated glial fibrillary acidic protein (citGFAP) is a citrullinated form of GFAP (Item No. 27353), a class III intermediate filament (IF) protein that is expressed in mature astrocytes and contributes to cytoskeletal structure and strength.{53009} GFAP can be citrullinated in a calcium-dependent manner on the arginine residue at position 270 (R270) and at R416 by protein arginine deiminase 1 (PAD1; Item No. 10784) and PAD2 (Item No. 10785).{53021} citGFAP levels are increased by the calcium ionophore ionomycin (Item No. 10004974) in an in vitro model of traumatic brain injury (TBI) using NHA CC-2565 human astrocytes and are induced by controlled cortical impact in the cerebral cortex in a rat model of TBI.{53020} It has been found in the hippocampus in a rat model of Alzheimer’s disease induced by amyloid-β (25-35), as well as in the retina in a mouse model of alkali-induced eye injury.{45561,45562} citGFAP has also been found in postmortem hippocampus from patients with Alzheimer’s disease, and citGFAP levels are increased in postmortem-derived brain lesions from patients with multiple sclerosis.{53021,35771} Cayman’s Citrullinated GFAP (R416) Monoclonal Antibody (Clone 4B8) can be used for ELISA, Immunohistochemistry, and Western blot applications. The antibody recognizes recombinant GFAP and citGFAP at 37 kDa.
Synonyms: ALXDRD|Glial Fibrillary Acidic Protein, Intermediate Filament Protein
Immunogen: A peptide from the C-terminal region of human GFAP citrullinated at R416
Formulation: 300 µg of Protein G-purified monoclonal antibody
Isotype: IgG1
Applications: ELISA, IHC, and WB
Origin:
Stability: 365 days
Application|ELISA||Application|Immunohistochemistry||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cell Biology|Cytoskeleton & Motor Proteins||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease||Research Area|Neuroscience|Ophthalmology
